Clinical Utility Of Two Novel Genes That Can Identify Patients At Higher Risk For Early Breast Cancer Recurrence

AviaraDx, Inc., formerly
known as Arcturus Bioscience, Inc., a leader in molecular cancer profiling,
announced today that a study, conducted in collaboration with Mayo Clinic,
demonstrated the clinical utility of two novel genes that can identify
patients at higher risk for early breast cancer recurrence and has been
published in the April 2006 issue of Clinical Cancer Research.


Researchers at Mayo Clinic tested the level of expression of the HOXB13
and IL17BR genes from paraffin-embedded tumor tissue derived from
postmenopausal women with early stage, estrogen positive breast cancer who
were enrolled in an earlier prospective tamoxifen study conducted by the
North Central Cancer Treatment Group. They demonstrated that the 2-gene
expression ratio was an independent marker of early breast cancer relapse
and overall survival in lymph node negative breast cancer patients, but not
lymph node positive tumors.


"The study with Mayo Clinic is the first of a series of clinical
studies conducted by AviaraDx, its clinical collaborators and independent
research groups, which we expect to be published in peer reviewed
scientific journals this year," said Antonius Schuh, Chief Executive
Officer of AviaraDx. "We are excited about the rapidly growing body of
evidence supporting the clinical utility of HOXB13 and IL17 in the
prediction of breast cancer recurrence and are expecting our diagnostic
licensing partners to launch a testing service based on both biomarkers in
2006."


AviaraDx discovered both biomarkers in a collaborative study with
Harvard Medical School and Mass. General Hospital which was published in
the June 2004 issue of Cancer Cell. As a result of this study, these two
biomarkers serve as the foundation of the AviaraDx Breast Cancer Recurrence
(BCR) Technology. Breast cancer is diagnosed in over 200,000 women each
year and claims the lives of over 40,000 in the United States alone. More
than 2/3 breast cancers are hormone positive, and most of these are early
stage (lymph node negative).


About AviaraDx, Inc.


AviaraDx, Inc., formerly Arcturus Bioscience, Inc., is a leader in
describing disease at the molecular level to enable molecular medicine and
the development of proprietary technologies for diagnostic applications in
oncology.


These technologies include the Molecular Cancer Identification
(MCID) technology which is based upon a set of clinically validated
molecular signatures relating to 90% of the most common cancers, and the
Breast Cancer Recurrence (BCR) Technology, which is based upon a
proprietary biomarker index for the prognosis of breast cancer recurrence
risk and metastatic potential.


Commercialization of the MCID Technology
commenced with its licensing partners Quest Diagnostics, and Laboratory
Corporation of America and Agendia BV for their Cancer of Unknown Primary
(CUP) diagnostic service. Quest Diagnostics has also licensed the BCR
Technology for the development of a diagnostic service. AviaraDx
technologies and intellectual properties position the Company to address
the multi-billion dollar market opportunities associated with the
development and commercialization for additional cancer diagnostics and
inventions to cost-effectively improve patient prognosis and response
prediction in cancer therapy.














AviaraDx has recently relocated its
headquarters from Mountain View, California to Carlsbad, California. Please
visit the AviaraDx website at aviaradx for more information.


Forward Looking Statements


AviaraDx, Inc. cautions you that statements included in this press
release that are not a description of historical facts are forward-looking
statements. For example, statements about the Company's expectations,
beliefs, plans, objectives, assumptions or future events or performance are
not historical facts and are all forward-looking statements. These
forward-looking statements are based upon AviaraDx's current expectations.
The Company's actual results and the timing of events may differ materially
from those set forth in this release as a result of certain risks and
uncertainties, including, without limitation: uncertainty regarding market
acceptance of the Company's technologies; rapid pace of technological
change in the identification and validation of proprietary biomarkers for
the prognosis of increased breast cancer recurrence risk; uncertainty of
product development and the associated risks related to clinical trials;
the risk that the U.S. Food & Drug Administration will not approve the
Company's products or technologies, or that such approval will be delayed
or require substantial additional testing and information, which could
result in increased costs and uncertainty; the Company's ability to
continue to conduct clinical trials; uncertainty relating to third party
reimbursement; the ability of the Company or its commercial partners to
convince health care professionals and third party payers of the medical
and economic benefits of the Company's products and technologies; the risk
of loss of collaborative arrangements with third parties; the difficulty in
managing growth and successfully managing resources; and other risks. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. We disclaim any
obligation to update these forward-looking statements, whether as a result
of new information, future events or otherwise.


AviaraDx, Inc.

aviaradx